Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exceptional Response to Trastuzumab in a Heavily Pretreated Patient With ERBB3-Mutated Metastatic Breast Cancer.

JCO precision oncology - 1 Jan 2021

Parmar Swapnil, Keck Jamie M, Kong Ben, Look Regan, Johnson Brett, Patterson Janice, Labrie Marilyne, Guimaraes Alexander R, Corless Christopher L, Beadling Carol, Kolodzie Annette, Bergan Raymond, Gray Joe W, Mills Gordon B, Mitri Zahi I

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to Breast Neoplasms
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Metastasis

Share to Receptor, ErbB-3

Share to Trastuzumab

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 34250408
DOI: 10.1200/PO.20.00183
PMCID: PMC8232752

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Exceptional Response to Trastuzumab in a Heavily Pretreated Patient With ERBB3-Mutated Metastatic Breast Cancer.PMID 34250408Read ↗

Exceptional Response to Pembrolizumab and Trastuzumab in a Heavily Pretreated Patient With HER2-Positive TMB-H and MSI-H Metastatic Breast Cancer.Semantic proximity Read ↗

Targeting HER2/HER3 co-mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy.Semantic proximity Read ↗

Advances in Targeting HER3 as an Anticancer TherapySemantic proximity Read ↗

Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer.Semantic proximity Read ↗

Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification.Semantic proximity Read ↗

Targeting HER3 for cancer treatment: a new horizon for an old targetSemantic proximity Read ↗

Exceptional Response to Olaparib: A Case Report of Metastatic Esophageal Squamous Cell Carcinoma in a Patient With Fanconi Anemia, Germline FANCA Mutation, and Somatic BRCA2 Mutations.Semantic proximity Read ↗

PI3K inhibition overcomes trastuzumab resistance: blockade of ErbB2/ErbB3 is not always enough.Semantic proximity Read ↗

Effects of Ado-Trastuzumab Emtansine and Fam-Trastuzumab Deruxtecan on Metastatic Breast Cancer Harboring HER2 Amplification and the L755S Mutation.Semantic proximity Read ↗

Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma.Semantic proximity Read ↗

Marked Response to Single Agent Trastuzumab in a Patient with Metastatic HER-2 Gene Amplified Rectal CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.